[go: up one dir, main page]

MX2023010535A - Antisense oligonucleotides for inhibiting alpha-synuclein expression. - Google Patents

Antisense oligonucleotides for inhibiting alpha-synuclein expression.

Info

Publication number
MX2023010535A
MX2023010535A MX2023010535A MX2023010535A MX2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A
Authority
MX
Mexico
Prior art keywords
antisense oligonucleotides
synuclein expression
inhibiting alpha
synuclein
alpha
Prior art date
Application number
MX2023010535A
Other languages
Spanish (es)
Inventor
Hélène Tran
Benjamin Chanrion
Sofia Lotfi
Dores Guillaume Das
Thierry Dorval
Raphaël Guignard
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2023010535A publication Critical patent/MX2023010535A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides antisense oligonucleotides for regulating expression of alpha-synuclein and use thereof to treat synucleinopathies.
MX2023010535A 2021-03-08 2022-03-07 Antisense oligonucleotides for inhibiting alpha-synuclein expression. MX2023010535A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21315033 2021-03-08
EP21306123 2021-08-17
PCT/EP2022/055770 WO2022189363A1 (en) 2021-03-08 2022-03-07 Antisense oligonucleotides for inhibiting alpha-synuclein expression

Publications (1)

Publication Number Publication Date
MX2023010535A true MX2023010535A (en) 2023-09-19

Family

ID=80738805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010535A MX2023010535A (en) 2021-03-08 2022-03-07 Antisense oligonucleotides for inhibiting alpha-synuclein expression.

Country Status (10)

Country Link
EP (1) EP4305168A1 (en)
JP (1) JP2024508956A (en)
AU (1) AU2022234522A1 (en)
CA (1) CA3212650A1 (en)
CL (1) CL2023002644A1 (en)
IL (1) IL305668A (en)
MX (1) MX2023010535A (en)
PE (1) PE20240696A1 (en)
TW (1) TW202305132A (en)
WO (1) WO2022189363A1 (en)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2916292A (en) 1991-10-24 1993-05-21 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
EP3561060A1 (en) * 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
CA2817960C (en) * 2010-11-17 2020-06-09 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2012109395A1 (en) * 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
EP3453761A1 (en) 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
WO2013159108A2 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CN117126846A (en) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 Oligonucleotide conjugates
DK2991656T3 (en) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc COMPOSITIONS AND PROCEDURES FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
SG11201510656PA (en) 2013-06-27 2016-01-28 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2018154418A1 (en) * 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
TWI809004B (en) * 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
PE20210172A1 (en) * 2018-01-12 2021-01-29 Roche Innovation Ct Copenhagen As ANTI-SENSE OLIGONUCLEOTIDES FOR ALPHA-SINUCLEIN AND USES THEREOF
JP7547201B2 (en) * 2018-01-12 2024-09-09 ブリストル－マイヤーズ スクイブ カンパニー Antisense oligonucleotides targeting alpha-synuclein and uses thereof - Patents.com
CN114072501A (en) 2019-05-06 2022-02-18 马萨诸塞大学 anti-C9 ORF72 oligonucleotides and related methods

Also Published As

Publication number Publication date
CA3212650A1 (en) 2022-09-15
PE20240696A1 (en) 2024-04-10
EP4305168A1 (en) 2024-01-17
WO2022189363A1 (en) 2022-09-15
IL305668A (en) 2023-11-01
AU2022234522A1 (en) 2023-10-26
CL2023002644A1 (en) 2024-04-01
JP2024508956A (en) 2024-02-28
TW202305132A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
PH12020500570A1 (en) Alpha-synuclein antisense oligonucleotides and uses thereof
MX2024006824A (en) Stat3 degraders and uses thereof.
EP2633052A4 (en) Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
MX358603B (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
MX2011009751A (en) Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
PH12013502620A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2011009752A (en) Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1.
GEAP202315297A (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2023001450A (en) COMPOSITIONS AND METHODS FOR INHIBITING <i>PLP1</i> EXPRESSION.
PH12022550130A1 (en) Enzyme inhibitors
MX2019008999A (en) Injectable composition for preventing hair loss or stimulating hair growth.
WO2012047956A3 (en) Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
MX2025006615A (en) Methods for altering body composition
NZ788953A (en) Methods of treating coronavirus
MX2023006542A (en) Jak1 pathway inhibitors for the treatment of vitiligo.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
MX2021004819A (en) Compositions and methods for treating brain injury.
MX2023004342A (en) Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors.
MX2023015102A (en) Pikfyve antisense oligonucleotides.
PH12021552866A1 (en) Compositions and methods for treating cancer
PH12022550078A1 (en) Enzyme inhibitors
BR112022009607A2 (en) AKT INHIBITORS TO IMPROVE CHIMERIC T-CELL PERSISTENCE